The role of vasodilators in the prevention and treatment of no-reflow following percutaneous coronary intervention.
The routine use of vasodilators in patients with acute coronary syndromes or other groups undergoing percutaneous coronary intervention (PCI) cannot be recommended at present. However, in the event of no-reflow occurring following PCI, intracoronary adenosine or verapamil should be administered.
Harding
S A
SA
D000241:Adenosine / Q000627:therapeutic use*; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D006801:Humans; D008833:Microcirculation / Q000187:drug effects; D009203:Myocardial Infarction / Q000628:therapy*; D015425:Myocardial Reperfusion / Q000379:methods; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014700:Verapamil / Q000627:therapeutic use*
D014665:Vasodilator Agents; D014700:Verapamil; D000241:Adenosine